Back to search results

Study of Computer Alerts for Peripheral Artery Disease Treatment

This study is looking at whether a computer alert system can help more patients with Peripheral Artery Disease (PAD), a condition where narrowed arteries reduce blood flow to your limbs, get the right lipid-lowering medicines. These medicines, like statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, or inclisiran, help lower "bad" cholesterol (LDL-C). The study will test if an on-screen alert for doctors and patients increases the number of prescriptions for these medicines. You might be able to join if you are 18 or older, have PAD, and are not currently taking any LDL-C lowering therapy. The main goal is to see how often these medicines are prescribed after 90 days. The study aims to include 400 patients, but its current status is unclear.

Study design
This is a randomized controlled trial involving 400 participants. It compares standard care to care where a computer alert system is used.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main outcome of the study is measured at 90 days after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06300450

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

Recruiting
NAAges 18+InterventionalTreatment
Brigham and Women's Hospital
~400 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Computer Alert

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of prescription of oral LDL-C-lowering therapy
Measured over 90 days

Conditions

Peripheral Artery Disease
Peripheral Vascular Diseases
Dyslipidemias

Explore related trials

DyslipidemiaPeripheral Artery Disease

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Gregory Piazza · PRINCIPAL_INVESTIGATOR · BWH

Who to contact

Gregory Piazza
[email protected]
6177326984
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients ≥ 18 years old
Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
Medical history entry, visit diagnosis, or problem list entry of PAD
Not prescribed LDL-C-lowering therapy

Exclusion

Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded

What this trial measures

  • Frequency of prescription of oral LDL-C-lowering therapy90 days

    The frequency of prescription of oral LDL-C-lowering therapy will be assessed using a report from the medical record